Wave Life Sciences targets once or twice yearly obesity treatment as INHBE program advances
Source: SeekingAlpha
2026-02-26 15:58:51 ET
More on Wave Life Sciences
- Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
- Wave Life Sciences: WVE-006 Now In Focus, Navigating Opportunity And Risk
- Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Wave Life Sciences GAAP EPS of -$0.30 misses by $0.03, revenue of $17.24M beats by $1.56M
- Wave Life Sciences Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Wave Life Sciences targets once or twice yearly obesity treatment as INHBE program advances
Wave Life Sciences Ltd.
NASDAQ: WVE
WVE Trading
-3.96% G/L:
$12.725 Last:
1,342,618 Volume:
$13.42 Open:
WVE Latest News
March 05, 2026 08:30:00 am
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
February 26, 2026 07:30:00 am
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
WVE Stock Data
$2,455,817,603
74,781,401
10.3%
63
N/A
Biotechnology & Life Sciences
Healthcare
SG
